Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mirum Pharmaceuticals in a research report issued to clients ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Hologic (HOLX – Research Report) yesterday and set a price target of $80.00.

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...